The Globe and Mail reports in its Wednesday edition that Apotex Inc. plans to go public this year with a share sale worth up to $1-billion that will allow its private equity owner to cash in on the generic drugmaker it acquired after the murder of its founder, Barry Sherman. The Globe's Andrew Willis and Sean Silcoff write that three years after acquiring Apotex from the estate of Mr. Sherman and his wife Honey, who were killed at their Toronto home in December, 2017, New York-based SK Capital Partners LP has hired investment banks to sell a minority stake in the company with an initial public offering. SK Capital is expected to maintain a controlling interest in Apotex after the IPO. Apotex is Canada's largest pharmaceutical company, with 6,000 employees churning out 25 billion doses of medicine each year and selling in 70 countries. Mr. Sherman founded the business in 1974 and was famously litigious, fighting court battles over drug patents with name-brand pharmaceutical companies and generic rivals. SK Capital, a private equity fund focused on life sciences, acquired Apotex in 2023 for an estimated $3-billion. Last fall, the fund manager hired RBC Capital Markets, Jefferies and TD Securities to lead the IPO.